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Abstract
Enterovirus 68 (EV68) was first isolated in 1962. Very few cases of EV68 infection were described over the ensuing 40 years.
However, in the past few years, an increase in severe respiratory tract infections associated with EV68 has been reported. We
identified two clusters of EV68 infection in South London, UK, one each in the autumn/winters of 2009 and 2010. Sequence
comparison showed significant homology of the UK strains with those from other countries including the Netherlands,
Japan and the Philippines, which reported EV68 outbreaks between 2008 and 2010. Phylogenetic analysis of all available
VP1 sequences indicated the presence of two modern EV68 lineages. The 2010 UK strains belonged to lineage 2. Lineage 1
could be further divided into two sub-lineages: some Japanese and Dutch strains collected between 2004 and 2010 form a
distinct sub-lineages (sub-lineage 1.1), whereas other strains from the UK, Japan, Netherlands and Philippines collected
between 2008 and 2010 represent sub-lineage 1.2. The UK 2009 strains together with several Dutch and Japanese strains
from 2009/2010 represents one variant (1.2.1), whereas those from the Philippines a second variant (1.2.2). Based on specific
deletions and substitutions, we suggest rules for the assignment of lineages and sub-lineages. Molecular epidemiological
analysis indicates rapid recent evolution of EV68 and this may explain the recent findings of a global resurgence of EV68.
Continuous global monitoring of the clinical and molecular epidemiology of EV68 is recommended.
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Introduction
Enterovirus 68 (EV68) is a unique virus in the enterovirus genus
as it shares characteristics with rhinoviruses, such as infection of
the respiratory tract and acid lability [1]. EV68 does not follow the
usual summer-autumn seasonality observed for most other
enterovirus species [2], although a recent outbreak in the
Netherlands occurred in the autumn of 2010 between September
and November [3]. It was first isolated from throat swabs collected
from four hospitalised children in 1962 in the USA [4] and
together with EV70 and EV94, was classified as enterovirus
species D. Rhinovirus 87 was found to be identical to EV68 and
reclassified into enterovirus species D [1,5,6]. Apart from
respiratory tract infections, EV68 has also been implicated in
some rare cases of fatal central nervous system infection [2,7]. An
American surveillance system reported the most common age
group affected by EV68 to be children aged between 1 and 4
years, but noted that about a quarter of all infections were
reported in adults [2]. A more recent study found .50% of all
EV68 infections occurred in adults over the age of 40 [3].
Since its initial discovery in the 1960s, EV68 infection was only
reported sporadically in the literature. Enterovirus surveillance in the
USA between 1970 and 2005 showed that EV68 was one of the most
rarely reported serotype with 26 reports observed over 36 years of
surveillanceinUSA [2]. However, in the last few years between 2008
and 2010, an increasing number of clusters of acute respiratory illness
associated with EV68 were reported in Asia, Europe, and the USA
[8,9,10,11,12,13]. Somerecent observations ofincrease incases could
be partly due to enhanced surveillance in patients with asthma [1].
However, a review of recent EV68 reports suggested that the increase
may not be entirely accounted for by reporting bias, as reports have
come independently from countries in different continents over the
same period and some countries, like USA and Japan, have been
conducting continuous enterovirus surveillance for many years. A
retrospective study in the Netherlands using samples dating back to
1996 confirmed the re-emergence of EV68 [3]. In many cases, EV68
was the sole enterovirus serotype detected and was associated with
severe or even fatal disease (Table S1).
Two clusters of EV68 infection were noted in our centre in South
London between November 2009 and December 2010. The first
cluster occurred during the winter of 2009 and the second in the
autumn/winter of 2010. We performed a molecular epidemiolog-
ical investigation of these EV68 strains and compared our findings
tothatofotherrecentviralsequencesreportedfrom othercountries.
Materials and Methods
Patients
As part of the work up during pandemic influenza seasons,
respiratory samples were obtained from patients with respiratory
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36005symptoms attending primary care or Guy’s and St. Thomas’
Hospitals in London, UK. Samples submitted to the diagnostic
laboratory between November 2009 and December 2010 were
investigated for viral pathogens using a multiplex nucleic acid
amplification panel (ResPlex II v2, Qiagen or xTAG RVP FAST
v1, Luminex). The nucleic acid targets of the multiplex panel
consisted of influenzaviruses A and B, parainfluenzaviruses 1–4,
respiratory syncytial viruses A and B, human metapneumovirus,
adenoviruses, coronaviruses, bocavirus and entero/rhinoviruses.
Respiratory specimens used include nasopharyngeal aspirate,
nasal swab, throat swab and bronchoalveolar lavage. Samples
that tested positive for entero/rhinovirus RNA were further
analysed by direct sequencing into individual enterovirus and
rhinovirus subtypes. This study was considered by the Chairman
of the Research Ethics Committee of St. Thomas’ Hospital and
was advised that ethical review of this study was not required
under the terms of the Governance Arrangements for Research
Ethics Committees in the UK (St Thomas’ Research Ethics
Committee Reference: 10/08). The demographics of EV68
positive patients and patients positive for other entero/rhinovirus-
es were compared by descriptive analyses. Pearson’s chi square
test, Fisher’s exact test or one-way ANOVA were used for analysis
and p-values,0.05 were considered significant. All analyses were
performed in SPSS Statistics 19.
Molecular Analysis
RNA was extracted from the clinical specimens using the
QIAamp Viral RNA Mini Kit (Qiagen) according to the
manufacturer’s instructions. cDNA was synthesised using random
primers (Invitrogen), M-MLV Reverse Transcriptase (Invitrogen)
and RNaseOut (Invitrogen) with 10 min at 25uC, 60 min at 37uC
and 5 min at 94uC. Samples were screened by PCR with the
HotStarTaq Master Mix Kit (Qiagen) targeting the 59NTR using
primers DK001 [14] and DK004 [15] under the following
conditions: 15 min at 95uC, 30 sec at 94uC, 30 sec at 53.4uC,
30 sec at 72uC (45 cycles) and 10 min at 72uC. Amplification of
the VP4/VP2 region was performed as above with primers VP4/2
F and VP4/2 R [16] or RCV556F (ACT ACT TTG GGT GTC
CGT GTT TC) and RCV886R (TTT CCR ATA GTG ATT
TGC TTK AGC C) with 60uC annealing and 40 cycles or 52uC
and 40 cycles, respectively. VP1 amplification was performed
using primers EV68-VP1-2325-fwn and EV68-VP1-3121-rvni or
EV68-VP1-2547-fwni and EV68-VP1-2772-rvni2 [13] with 55uC
annealing temperature and 40 cycles.
Bidirectional sequencing was performed by LGC Genomics
GmbH (Berlin, Germany) or in house (PCR product cleaning with
microClean (Microzone), cycle sequencing with BigDye Termi-
nator v3.1 Cycle Sequencing Kit (Applied Biosystems) on the
automated sequencer 3130xl Genetic Analyzer (Applied Biosys-
tems)).
Sequence Analysis
Sequence analysis was performed using the software BioEdit
(version 7.0.9) and MEGA5 (version 5.03). Phylogenetic trees were
generated using the neighbour-joining method with Kimura 2-
parameter as substitution model and pairwise deletion for gaps
and missing data. The Bootstrap method was chosen for the
phylogenetic test with 1000 replications. All available GenBank
entries submitted for 59NTR (n=46), VP4 (n=93), VP1 (n=201)
and full genomes or coding sequences (n=6) for EV68 were
included in the analysis (Table S2). Sequences from this study were
Table 1. Clinical and demographic details of EV68 positive and other entero/rhinovirus positive patients.
EV68 positive
patients (%)
Other positive
patients (%) OR (95% CI) p- value
Total 17 254 na na
Age (years) (mean, median) 10.2, 5.1 12.4, 1.4 na 0.669
Male 10 (58.8%) 148 (58.3%) 0.977 (0.360–2.650) 0.964
Hospital admission 16 (94.1%) 240 (94.5%) 1.071 (0.132–8.670) 1
Admitted from Accident & Emergency Department 8 (47.1%) 84 (33.1%) 0.556 (0.207–1.492) 0.238
Lengths of stay (days) (mean, median) 6.6, 3 18.3, 5 na 0.316
Incidental finding 1 (6.3%) 50 (19.7%) 3.676 (0.474–28.494) 0.321
Mild infection 7 (43.8%) 103 (40.6%) 0.877 (0.317–2.430) 0.801
Severe infection
1 8 (50%) 101 (39.8%) 0.660 (0.240–1.816) 0.418
Underlying risk factors 13 (81.3%) 185 (72.8%) 0.619 (0.171–2.238) 0.571
Death 1 (6.3%) 17 (6.7%) 1.081 (0.135–8.677) 1
Chronic respiratory diseases 9 (56.3%) 65 (25.6%) 0.267 (0.096–0.747) 0.017
Chronic heart diseases 3 (18.8%) 45 (17.7%) 0.933 (0.255–3.410) 1
Chronic neurological diseases 1 (6.3%) 28 (11%) 1.858 (0.236–14.610) 1
Immunosupression 3 (18.8%) 40 (15.7%) 0.810 (0.221–2.972) 0.726
Other risk factors 3 (18.8%) 70 (27.6%) 1.649 (0.456–5.960) 0.570
Upper respiratory tract infection 3 (18.8%) 104 (40.9%) 3.004 (0.835–10.806) 0.078
Airway disease (e.g. asthma) 7 (43.8%) 48 (18.9%) 0.300 (0.106–0.845) 0.025
Lower respiratory tract infection 6 (37.5%) 102 (40.2%) 1.118 (0.394–3.173) 0.833
Coinfection 2 (12.5%) 63 (24.8%) 2.309 (0.511–10.438) 0.372
1An infections was classified as severe if the patient required intensive care, attended a high dependency unit or died.
doi:10.1371/journal.pone.0036005.t001
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doi:10.1371/journal.pone.0036005.g001
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Results
Of the 473 entero/rhinovirus positive respiratory specimens
collected between November 2009 and December 2010, a total of
403 were available for this study. Of these, 342 (85%) could be
sequenced, of which 36 enteroviruses (10.5%) were identified
(n=22 by 59NTR and VP4/VP2, n=12 by 59NTR only and
n=2 by VP4/VP2 only). Half of these enteroviruses were
identified as EV68 (18 specimens from 17 patients). The EV68
specimens were collected in two separate clusters – the first cluster
occurred between November and December of 2009 (n=9) and a
second cluster between September and December 2010 (n=8). No
EV68 was detected in between the two winter seasons. The patient
age ranged from 7 weeks to 45 years (mean 12.2 years, median 5.8
years) with a male:female ratio of 10:7. Apart from one specimen
from primary care, the majority of patients were hospitalised
(n=16) with 8 patients requiring intensive care. A co-pathogen
was detected in 2 patients with severe illness, one HIV infected
patient with cytomegalovirus, and another with Neisseria meningitidis
septicaemia. Most patients (n=14) had underlying medical
conditions, the majority being chronic respiratory illnesses (n=9,
p=0.017). The HIV infected patient died. EV68 infection was
also significantly associated with airway diseases such as asthma
(p=0.025) (Table 1).
Nucleotide and phylogenetic analysis
The RNA sequences of EV68 detected in 2010 were different
from that of 2009. The only exception was strain 09-70 which
came from a sample from December 2009, but its 59NTR and
VP1 sequences clustered with the 2010 EV68 strains. The overall
nucleotide similarity within each cluster were at least 99.7% and
99.1% in the 59NTR, 98.9% and 97.7% in the VP4/VP2, and
98.5% and 97.5% in the VP1 region for the 2009 and 2010
(including the strain 09-70) respectively.
59NTR. As expected, the conserved 59NTR showed a high
degree of similarity between the two clusters (.95.8%). They both
showed a high degree of homology to the prototype Fermon strain
from 1962 (.95.3%) and the full length French strain 37–99 from
1998 (.97.5%). However, the 2010 59NTR sequences showed
more divergence in comparison to recent Filipino sequences from
Figure 2. 59NTR sequences preceding VP4 showing the two deletion blocks.
doi:10.1371/journal.pone.0036005.g002
Table 2. Sequence variations in 59NTR between UK 2009 and 2010 EV68 sequences.
Position
1 Mutation
1 Found in Also found in
222* TRC 2009 (except 09-116) All Japan (2010), 11/15 US (1989–2003), 1/4 Brazil (2007)
279 TRC 2009 4/21 Philippine (2008/09)
318+319 TRC+CRT 2010 None
333 GRA 2009 All Japan (2010), all Philippine (2008/09), 10/15 US (1989–2003), 1/4 Brazil (2007)
345 CRT 2010 All Brazil (2007), 1/21 Philippine (2008/09), 1/15 US (2003)
471* CRT 2010 All Japan (2010), France (1998), all Brazil (2007), 11/15 US (1989–2003)
495* ARG 2009 None
518* CRT 2009 (and 10-202) All Japan (2010), France (1998), 13/15 US (1962–2003)
1reference Fermon strain (AY426531).
*Filipino sequences not amplified into this region.
doi:10.1371/journal.pone.0036005.t002
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2010). Phylogenetic analysis of this region showed close clustering
of the 2009 UK strains with 6 other Filipino strains from 2008,
whereas the 2010 UK strains together with the 2009 09-70 strains
form a separate cluster (Figure 1). Comparing the sequence from
2009 and 2010 showed the presence of eight nucleotide variations
between the two years in the 59NTR (Table 2). Several of these
mutations are reported for the first time (T318C and C319T in
2010, and A495G in 2009 sequences, using the Fermon strain as
reference). In addition, two blocks of deletions (681–704 and 717–
727) were noted in the 59NTR among the more recently reported
Japanese isolates from the literature compared to the Fermon
strain [11]. Our 2009 and 2010 strains also had these deletions
although the islet region between the two deletion blocks (705–
716) differed in at least 5 out of 12 nucleotides compared to the
Japanese strains (Figure 2). Additionally, whereas the 2009 UK
strains had both deletion blocks (681–703 and 717–728), the 2010
strains (including 09-70) only had the deletion between 681–704.
Whether or not these deletion blocks occurred in other EV68
strains is not known, as other EV68 59NTR sequences reported in
the GenBank were not extended to cover this pre-VP4 region of
the 59NTR.
VP4/VP2. The VP4/VP2 region showed a much greater
difference between the two clusters (87.4%–89.7% nucleotide
similarities) but retained a high conservation in the protein
(97.9%–98.6% amino acid similarities). The UK 2009 sequences
had a high degree of homology to 6 other Japanese sequences from
2010 (Figure 3). For example, the Yamagata 2035 strain from
2010 was 98.4% similar to the UK 09-398 strain, but only 89.2%
similar to the UK 10-268 strain. On the other hand, the UK 2010
sequences were more similar to another cluster of Japanese strains
from the same year (Figure 3). For example, the Yamagata 2076
strain also from 2010 was 98.1% similar to the UK 10-268 strain,
but only 90.0% similar to the UK 09-398 strain. The UK 2010
sequences also showed a high degree of homology to some older
European sequences. The 2008 Swiss F91-1008-U strain showed
98.6% and the 2008 Italian Pav250-20260 strain 98.0% similarity
to UK 10-268 strain. The corresponding homology to the UK 09-
398 strain was 90.7% and 91.0% respectively. Overall, the amino
acid composition in the VP4 protein (1–69) showed a high degree
of conservation (only change was I19V in Yamaguchi/Yu/50.10).
In the VP2 region, there were only four amino acid changes
compared to the Fermon strain (Figure 4). Interestingly, whereas
UK 2009 strains showed the same substitutions as the 1998 French
and 2010 Japanese JPOC strains (S142A and N143G), the UK
2010 isolates have different substitutions at these positions (S142T
and N143E). All other available sequences were not extended to
cover this region.
VP1. VP1 is the region in which the largest number of
sequences of previous isolates was available from the GenBank.
The homologies between the 2009 and 2010 (including 09-70) UK
sequences in this region were between 86.3%–90.7% (nucleotides,
Table 3) and 91.0%–95.0% (amino acids, Table 4). Distinct
clustering of sequences from the two years was again clearly
observed (Figure S1, S2, S3). The UK 2009 sequences were most
similar to 7 Japanese strains from 2010 (same as for VP4/VP2)
and 14 Dutch strains from 2009/2010. The 2010 UK sequences
(including 09-70), on the other hand, were most similar to a
number of other Dutch strains from 2006–2010 and 6 other
Japanese strains from 2010 (same as for VP4/VP2). No VP1
Figure 3. Phylogenetic analysis of VP4/VP2. First two letters of
sequences are collection year, followed by letters for the country of
origin.
doi:10.1371/journal.pone.0036005.g003
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available for comparison. Both the 2009 and 2010 UK VP1
sequences diverged significantly from the prototype Fermon strain
(maximal homology of 88.1% and 89.3% respectively), but were
closer to another earlier full genome sequence from France (strain
37–99 from 1998 – 93.5% and 91.8% maximal homology
respectively). All Filipino sequences from 2008/2009, including
the ones which clustered closely with the UK 2009 sequences at
the 59NTR, form a distinct cluster at the VP1 region, the separate
branching of which was supported by a bootstrap value of 98
(Figure S2). A three nucleotide deletion (ATG), resulting in the
deletion of glycine at position 141 in the VP1 protein (Figure S4)
[13], was noted for all UK 2010 strains and all strains clustering
closely, including strains from the Netherlands (2001–2010), USA
(2003), Finland (2004/2005) and Japan (2006–2010).
Lineages
Phylogenetic analysis of all available VP1 sequences showed
that all modern EV68 strains were derived from two separate
lineages, supported by a bootstrap value of 88 (Figure 5).
The 2010 UK EV68 strains (including 09-70) share the same
lineage as some of the 2006–2010 Dutch and 2010 Japanese
strains. This we will refer to as lineage 2. Characteristic for this
lineage is the glycine deletion in position 141 in the VP1 protein.
Additionally, the amino acid change at position 142 and 143 to
threonine and glutamic acid in the VP2 protein could also be
linked to this lineage. The presence of the one deletion block (681–
704) in the 59NTR is also a characteristic feature. Additional
sequences covering this region are required for verification;
however 2010 isolates from Yamagata which clustered within
lineage 2 have limited sequence data available which suggest the
absence of the second deletion block (717–727) (Figure S5).
Lineage 1, on the other hand, can be divided into further sub-
lineages. One branch of this lineage consisted of a number of
Dutch strains (2004–2009) and Japanese isolates from Yamagata
and Osaka (2005–2010) (sub-lineage 1.1). The UK 2009 EV68
strains also share the same lineage with some of the 2009/2010
Dutch and Japanese strains (variant 1.2.1), but are distinct from
another branch consisting of the 2008/2009 Filipino isolates
(variant 1.2.2). All these branches were supported by a strong
bootstrap value .92. The nucleotide and amino acid homologies
between the lineages, sub-lineages and variants were shown in
Tables 5 and 6. The two variants showed 96%–98% nucleotide
similarities with each other, compared to 89%–95% with sub-
lineage 1.1 and 84%–93% with lineage 2. Similarly, sub-lineage
1.1 shared 85%–92% with lineage 2. Within each lineage, the
similarity was between 95%–100%. Whereas in the UK, the two
lineages predominated in different years (lineage 1.2.1 in 2009 and
lineage 2 in 2010), in other countries such as the Netherlands and
Figure 4. Protein sequence for VP4/VP2 of all available sequences.
doi:10.1371/journal.pone.0036005.g004
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same year.
Discussion
The epidemiology of EV68 is intriguing. It was first described in
1962 [4] but in the ensuing 40 years, it was reported only
sporadically despite regular enterovirus surveillance by public
health bodies [2]. Over the last decade, and particularly in the last
few years, the number of reports of EV68 increased dramatically
and in some cases severe respiratory tract infections [3,8,9,11,13]
and even central nervous system infections [2,7] were reported. An
increase in detection rate may be due to improved testing methods
or an increase in multiplex molecular testing of respiratory samples
as a result of enhanced respiratory virus surveillance. However, it
is not possible to discount the possibility that EV68 is an emerging
pathogen. A recent study retrospectively investigated the molec-
ular evolution of EV68 in the VP1 region with time [3] and
showed that the original Fermon strain and clusters of selected
older sequences (1989–2002) disappeared over time with subse-
quent emergence and increase in number of recent strains. The
presence of three separate lineages of EV68 has been proposed,
but not all available EV68 strains were used in that study [3]. We,
however, performed more detailed analyses, adding new sequenc-
es from the UK from 2009 and 2010, and including all available
EV68 sequences from the GenBank covering 59NTR, VP4/VP2
as well as VP1.
In our study over two winters, about 10% of the respiratory
entero/rhinovirus detection in respiratory samples using a
commercial multiplex PCR test were enteroviruses and 50% of
these respiratory enteroviruses were confirmed as EV68, which
was detected in two consecutive winter season with no detection in
the summer period between the two winters. The pattern of illness
associated with EV68 was very similar to that of rhinoviruses and
could be associated with severe respiratory tract infection. In our
cohort, 8 patients required admission to intensive care unit.
Compared to other entero/rhinovirus infection, EV68 was
significantly associated with underlying chronic pulmonary
diseases and asthma (Table 1).
Apart from a single strain from December 2009, EV68
circulating in South-East London in 2009 was different from that
circulated in 2010. The differences between the strains from the
two years were supported by phylogenetic analysis of sequences
from the 59NTR, VP4/VP2 and VP1 regions. The two viral
lineages showed various degree of similarity with EV68 isolates
from other years in other countries. Despite this difference, EV68
remains monophyletic as the sequence homology of global isolates
over time remain .90% in all gene regions studied. However,
contemporary EV68 strains diverge significantly from the original
1962 Fermon isolate, which showed 82.8%–89.3% nucleotide
similarities in VP1 (88.1%–92.5% for amino acids).
A previous study based only on VP1 suggested that there were
three separate lineages of EV68 [3]. However, the phylogenetic
analysis in this study of global EV68 isolates suggested the
presence of 2 modern lineages with one showing two sub-lineages
and the presence of variants. We propose the following
characteristics for the assignment to lineage 2:
Table 3. Nucleotide identities in the VP1 region for clusters
and lineages.
within UK 2009 UK 2010
n MIN MAX MIN MAX MIN MAX
Variant 1.2.1 27 97.4% 100.0%
UK 2009 6 98.5% 100.0% 98.5% 100.0% 86.3% 90.7%
Netherlands 2009–2010 10 97.8% 100.0% 98.0% 100.0% 87.3% 90.9%
Netherlands 2009* 4 98.5% 99.7% 97.9% 100.0% 87.3% 89.7%
Japan Yamagata 2010 7 99.2% 100.0% 98.3% 99.5% 87.3% 90.6%
Variant 1.2.2 16 97.6% 100.0%
Philippines 2008 16 97.6% 100.0% 96.1% 98.1% 83.7% 92.3%
Sub-lineage 1.1 70 94.7% 100.0%
Japan JPOC CG/cds
1
2010
4 98.5% 99.6% 89.2% 93.8% 84.8% 90.6%
Japan Yamagata
2005–2007
11 98.9% 100.0% 91.7% 94.8% 86.3% 91.3%
Netherlands 2004–2009 18 94.7% 100.0% 90.3% 92.6% 85.3% 90.2%
Japan JPOC 2010 10 98.6% 100.0% 90.2% 93.8% 84.8% 90.3%
Japan Yamagata 2010 27 98.8% 100.0% 89.7% 93.5% 85.3% 90.3%
Lineage 2 68 96.1% 100.0%
UK 2010 10 97.5% 100.0% 86.3% 90.7% 97.5% 100.0%
Netherlands 2010 16 97.7% 100.0% 88.2% 90.9% 96.6% 100.0%
Netherlands 2006–2010* 11 96.7% 100.0% 86.9% 89.7% 96.1% 99.5%
Netherlands 2009–2010* 23 98.5% 100.0% 86.8% 90.2% 97.3% 100.0%
Japan Yamagata 2010 6 98.6% 100.0% 87.4% 90.4% 97.6% 100.0%
1CG: complete genome, cds: coding sequence.
doi:10.1371/journal.pone.0036005.t003
Table 4. Amino acid identities in the VP1 region for clusters
and lineages.
within UK 2009 UK 2010
n MIN MAX MIN MAX MIN MAX
Variant 1.2.1 27 97.2% 100.0%
UK 2009 6 98.5% 100.0% 98.5% 100.0% 91.0% 95.0%
Netherlands 2009–2010 10 97.6% 100.0% 98.0% 100.0% 91.0% 95.5%
Netherlands 2009* 4 98.2% 100.0% 97.3% 100.0% 91.1% 94.0%
Japan Yamagata 2010 7 99.0% 100.0% 98.5% 100.0% 92.5% 94.5%
Variant 1.2.2 16 96.9% 100.0%
Philippines 2008 16 96.9% 100.0% 97.6% 100.0% 88.1% 95.3%
Sub-lineage 1.1 70 97.3% 100.0%
Japan JPOC CG/cds
1
2010
4 99.5% 99.8% 95.0% 97.0% 92.9% 97.0%
Japan Yamagata 2005–
2007
11 99.7% 100.0% 96.0% 97.0% 93.9% 97.0%
Netherlands 2004–2009 18 97.3% 100.0% 94.7% 97.0% 92.0% 98.5%
Japan JPOC 2010 10 99.0% 100.0% 95.0% 97.0% 92.9% 97.0%
Japan Yamagata 2010 27 99.0% 100.0% 95.5% 97.0% 93.4% 97.0%
Lineage 2 68 97.0% 100.0%
UK 2010 10 98.5% 100.0% 91.0% 95.0% 98.5% 100.0%
Netherlands 2010 16 98.8% 100.0% 92.5% 95.5% 97.0% 100.0%
Netherlands 2006–
2010*
11 97.3% 100.0% 89.3% 95.5% 97.0% 100.0%
Netherlands 2009–
2010*
23 98.9% 100.0% 88.9% 94.0% 98.4% 100.0%
Japan Yamagata 2010 6 100.0% 100.0% 92.9% 95.5% 97.6% 100.0%
1CG: complete genome, cds: coding sequence.
doi:10.1371/journal.pone.0036005.t004
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B) Amino acid change at position 142 and 143 to threonine and
glutamic acid in the VP2 protein;
and C) Presence of only one deletion block from 681–704 in the
59NTR.
Nucleotide similarities cannot be used to characterise the
lineages, sub-lineages and variants as the ranges of percentage
homology overlap (84–93% similarities between lineages, 89–95%
between sub-lineages and 96–98% between variants, Table 5).
Worth mentioning is the difference in VP2, a surface protein on
EV68. In the Fermon strain the amino acids serine and asparagine
with polar uncharged side chains are in position 142 and 143. The
side chains of alanine and glycine in lineage 1 are hydrophobic
and neutral, whereas threonine and glutamic acid in lineage 2 are
polar uncharged and negatively charged. These amino acid
Figure 5. Phylogenetic analysis of VP1. First two letters of sequences are collection year, followed by letters for the country of origin. The
subtrees of sub-lineages 1.1 and 1.2 and lineage 2 were collapsed for easy viewing. Figure S1 shows the uncollapsed version. Full details on each
lineage can be viewed in Figure S2 and S3.
doi:10.1371/journal.pone.0036005.g005
Table 5. Nucleotide identities in the VP1 region for lineages.
Variant 1.2.1 Variant 1.2.2 Sub-lineage 1.1 Lineage 2
MIN MAX MIN MAX MIN MAX MIN MAX
Original 80.9% 89.6% 79.8% 87.2% 83.5% 88.3% 83.1% 89.3%
Variant 1.2.1 97.4% 100.0% 95.6% 98.1% 89.2% 94.8% 86.3% 91.1%
Variant 1.2.2 97.6% 100.0% 89.7% 94.9% 83.7% 92.9%
Sub-lineage 1.1 94.7% 100.0% 84.8% 92.2%
Lineage 2 96.1% 100.0%
doi:10.1371/journal.pone.0036005.t005
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altered antigenicity.
Sub-lineages 1.1 and 1.2 possibly could be assigned on the basis
of the nucleotide sequence in the islet region in the 59NTR
deletion. Limited data available from 2010 Yamagata isolates
suggest a differentiation according to the nucleotide composition
in the islet region (705–716) and one nucleotide difference in the
lengths of both deletion block (681–703 and 717–728 for sub-
lineage 1.1) (Figure S5). However, more sequences are needed for
verification.
While the 2 lineages predominated in the UK in different years,
co-circulation of lineages was observed in other countries. The
relatedness between strains from different countries suggests that
EV68 circulated rapidly between countries and continents. It is
also possible that the prevalence of the EV68 strains in each
country is dictated by the local herd immunity. A study in Finland
has shown a high population seroprevalence of EV68 [17]. Hence,
EV68 has been circulating in the community for many years. The
lack of previous detection may be due to the presence of many
transient and sub-clinical infections which were not tested. EV68 is
an RNA virus with known potential of undergoing antigenic
change. This study corroborates previous evidence that a rapid
change is occurring in EV68, as reported for other human
enteroviruses such as EV71 and echovirus 30 [18,19,20].
Recombination between the same species of enteroviruses is a
common phenomenon [21], therefore effort should be made to
monitor this possibility between EV68 and other species D
enteroviruses such as EV70, EV94 and EV111. So far, no
evidence of inter-typic recombination between 59NTR and VP1
was observed from our limited sequence data and that in the
literature (Figure S6). Only few studies of EV68 have investigated
multiple genomic regions (Table S2) which greatly restricted the
analysis of inter-typic and inter-lineage recombination. No
bootstrap supported clustering between the lineages could be
identified in the 59NTR due to the high conservation in this region
which prevented the analysis of inter-lineage recombination
between 59NTR and VP1. No evidence of inter-lineage recom-
bination of strains was observed on analysis of available sequences
covering VP4/VP2 and VP1 (n=70). Apart from the 4 full
genome sequences, only the American sequences (n=15, 1963–
2003) cover the 3D polymerase region. The reporting of more full
viral genome sequences is required to help in the analysis of
recombination.
This study was limited by the lack of sequence information on
all target regions for each strain. The presence or absence of
deletion blocks in the 59NTR immediately preceding VP4 was not
certain in most strains, as this region was not covered in most
available sequences in the GenBank. Continuous surveillance and
longer term study of sequences over several years is needed to
establish the pattern of evolution and to understand the dynamics
of transmission between countries and continents.
In conclusion, the recent increase in reports of EV68 could be
due to improved surveillance and detection techniques, but may
also be a real resurgence as a result of sequence variation
interacting with population host immunity. This study suggested
that modern EV68 strains consisted of two lineages and further
sub-lineages; and that the global spread of EV68 has been
occurring between and within continents in the past few years.
Hence, EV68 is an emerging pathogen that requires global
monitoring.
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Figure S1 Phylogenetic analysis of VP1 (uncollapsed).
(TIF)
Figure S2 Expansion of the phylogenetic analysis of VP1
for lineage 1.
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Figure S3 Expansion of the phylogenetic analysis of VP1
for lineage 2.
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Figure S4 Deletion of glycine in position 141 of the VP1
protein in lineage 2.
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Figure S5 Deletion in the 59NTR.
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Figure S6 Phylogenetic analysis of group D enterovirus
strains where both 59NTR and VP1 sequences were
available, showing the absence of inter-typic recombi-
nation.
(TIF)
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Table 6. Amino acid identities in the VP1 region for lineages.
Variant 1.2.1 Variant 1.2.2 Sub-lineage 1.1 Lineage 2
MIN MAX MIN MAX MIN MAX MIN MAX
Original 86.6% 93.0% 85.2% 90.8% 88.6% 96.1% 86.6% 92.9%
Variant 1.2.1 97.2% 100.0% 94.9% 100.0% 93.9% 97.0% 88.9% 95.9%
Variant 1.2.2 96.9% 100.0% 93.1% 96.9% 88.1% 95.9%
Sub-lineage 1.1 97.3% 100.0% 91.1% 98.5%
Lineage 2 97.0% 100.0%
doi:10.1371/journal.pone.0036005.t006
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